EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease

Livius Penter iD, Yang Liu iD, Jacquelyn O Wolff, Lin Yang iD, Len Taing, Aashna Jhaveri, Jackson Southard iD, Manishkumar Patel iD, Nicole M Cullen, Kathleen L Pfaff, Nicoletta Cieri iD, Giacomo Oliveira iD und 25 weitere

Blood · 2023

DOI: 10.1182/blood.2022018246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Livius Penter und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The challenge of eradicating leukemia in patients with acute myelogenous leukemia (AML) after initial cytoreduction has motivated modern efforts to combine synergistic active modalities including immunotherapy. Recently, the ETCTN/CTEP 10026 study tested the combination of the DNA methyltransferase inhibitor decitabine together with the immune checkpoint inhibitor ipilimumab for AML/myelodysplastic syndrome (MDS) either after allogeneic hematopoietic stem cell transplantation (HSCT) or in the HSCT-naïve setting. Integrative transcriptome-based analysis of 304 961 individual marrow-infiltrating cells for 18 of 48 subjects treated on study revealed the strong association of response with a high baseline ratio of T to AML cells. Clinical responses were predominantly driven by decitabine-induced cytoreduction. Evidence of immune activation was only apparent after ipilimumab exposure, which altered CD4+ T-cell gene expression, in line with ongoing T-cell differentiation and increased frequency of marrow-infiltrating regulatory T cells. For post-HSCT samples, relapse could be attributed to insufficient clearing of malignant clones in progenitor cell populations. In contrast to AML/MDS bone marrow, the transcriptomes of leukemia cutis samples from patients with durable remission after ipilimumab monotherapy showed evidence of increased infiltration with antigen-experienced resident memory T cells and higher expression of CTLA-4 and FOXP3. Altogether, activity of combined decitabine and ipilimumab is impacted by cellular expression states within the microenvironmental niche of leukemic cells. The inadequate elimination of leukemic progenitors mandates urgent development of novel approaches for targeting these cell populations to generate long-lasting responses. This trial was registered at www.clinicaltrials.gov as #NCT02890329.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationHumansIpilimumabDecitabineRecurrence

Substanzen

IpilimumabDecitabine

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA.
  • Harvard Medical School, Boston, MA.
  • Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
  • Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA.

ORCID-Profile: Livius Penter, Yang Liu, Lin Yang, Jackson Southard, Manishkumar Patel, Nicoletta Cieri, Giacomo Oliveira, Elizabeth A Morgan, Sacha Gnjatic, Kenneth J Livak, Jennifer Altreuter, Jacqueline S Garcia, Catherine J Wu

Förderung

  • NCI NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Penter, L., Liu, Y., Wolff, J. O., Yang, L., Taing, L., Jhaveri, A., Southard, J., Patel, M., Cullen, N. M., Pfaff, K. L., Cieri, N., Oliveira, G., Kim-Schulze, S., Ranasinghe, S., Leonard, R., Robertson, T., Morgan, E. A., Chen, H. X., Song, M. H., …, & Wu, C. J. (2023). Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. https://doi.org/10.1182/blood.2022018246

Vancouver

Penter L, Liu Y, Wolff JO, Yang L, Taing L, Jhaveri A, et al. Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023. doi:10.1182/blood.2022018246

BibTeX
@article{Penter2023,
  author = {Penter, Livius and Liu, Yang and Wolff, Jacquelyn O and Yang, Lin and Taing, Len and Jhaveri, Aashna and Southard, Jackson and Patel, Manishkumar and Cullen, Nicole M and Pfaff, Kathleen L and Cieri, Nicoletta and Oliveira, Giacomo and Kim-Schulze, Seunghee and Ranasinghe, Srinika and Leonard, Rebecca and Robertson, Taylor and Morgan, Elizabeth A and Chen, Helen X and Song, Minkyung H and Thurin, Magdalena and Li, Shuqiang and Rodig, Scott J and Cibulskis, Carrie and Gabriel, Stacey and Bachireddy, Pavan and Ritz, Jerome and Streicher, Howard and Neuberg, Donna S and Hodi, F Stephen and Davids, Matthew S and Gnjatic, Sacha and Livak, Kenneth J and Altreuter, Jennifer and Michor, Franziska and Soiffer, Robert J and Garcia, Jacqueline S and Wu, Catherine J},
  title = {Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022018246}
}
Kostenlos starten →